Recent years have seen FDA approval of several RTK inhibitors, including sunitinib (targets include VEGFR and PDGFR) for the treatment of gastrointestinal stromal tumor and sorafenib (targets include Raf, PDGFR, VEGFR) for the treatment of advanced renal cell carcinoma and other tumor types. This evidence concerns the gene KDR and gastrointestinal stromal tumor.